Evidence map›Paper›PMID 39417102›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide.

Geno Guerra, George Wendt, Lucie McCoy, Helen M Hansen, Linda Kachuri, Annette M Molinaro, Terri Rice, Victoria Guan, Lianne Capistrano, Allison Hsieh and 10 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Geno GuerraDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9870-9998
George WendtDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Lucie McCoyDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Helen M HansenDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Linda KachuriDepartment of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0002-3226-4727
Annette M MolinaroDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9854-7404
Terri RiceDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Victoria GuanSchool of Pharmacy, University of California San Francisco, San Francisco, CA, USA.
Lianne CapistranoSchool of Pharmacy, University of California San Francisco, San Francisco, CA, USA.
Allison HsiehSchool of Pharmacy, University of California San Francisco, San Francisco, CA, USA.
Veruna KalsiSchool of Pharmacy, University of California San Francisco, San Francisco, CA, USA.
Jaimie SalleeSchool of Pharmacy, University of California San Francisco, San Francisco, CA, USA.
Jennie W TaylorDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Jennifer L ClarkeDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Eduardo Rodriguez AlmarazDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0978-1117
John K WienckeDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Jeanette E Eckel-PassowDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Robert B JenkinsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Margaret WrenschDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3070-7600
Stephen S FrancisDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
Targeted MV-CEA as a Potent Antitumor Agent against GBMP50CA108961 · NCI · MAYO CLINIC ROCHESTER · PI O'NEILL, BRIAN PATRICK · 2004 to 2015
$22.5M
GENETIC EPIDEMIOLOGY OF MALIGNANT GLIOMAR01CA052689 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K., WRENSCH, MARGARET R. · 1991 to 2015
$20.5M
International Case Control Study of Malignant GliomaR01CA139020 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BONDY, MELISSA L. · 2010 to 2015
$16.0M
UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMASR01CA230712 · NCI · MAYO CLINIC ROCHESTER · PI JENKINS, ROBERT B. · 2018 to 2022
$3.3M
Discovering Infection-mediated Pathways of Glioma Etiology and Prognosis by Leveraging Multiplex Serology and ImmunogenomicsR01CA266676 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FRANCIS, STEPHEN STARKO · 2022 to 2025
$2.6M
Biomarkers of survival in glioma epidemiologyR01CA126831 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K. · 2008 to 2013
$2.5M
Training in the Molecular & Genetic Epidemiology of CancerT32CA112355 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHENG, IONA C, ZIV, ELAD · 2020 to 2024
$1.8M
Comprehensive Investigation of Multiple Myeloma Genetic Susceptibility in African AmericansR00CA246076 · NCI · STANFORD UNIVERSITY · PI KACHURI, MIRLINDA · 2022 to 2024
$747k
NCCDPHP CDC HHS NU58DP006344NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INCI NIH HHS P50 CA097257NCI NIH HHS P50 CA108961NCI NIH HHS R00 CA246076NCI NIH HHS R01 CA052689NCI NIH HHS R01 CA126831NCI NIH HHS R01 CA139020NCI NIH HHS R01 CA230712NCI NIH HHS R01 CA266676NCI NIH HHS T32 CA112355NCRR NIH HHS UL1 RR024131
6 · The paper itself

Abstract

Background: Temozolomide (TMZ) treatment has demonstrated, but variable, impact on glioma prognosis. This study examines associations of survival with DNA repair gene germline polymorphisms among glioma patients who did and did not have TMZ treatment. Identifying genetic markers which sensitize tumor cells to TMZ could personalize therapy and improve outcomes. Methods: We evaluated TMZ-related survival associations of pathogenic germline SNPs and genetically predicted transcript levels within 34 DNA repair genes among 1504 glioma patients from the UCSF Adult Glioma Study and Mayo Clinic whose diagnoses spanned pre- and post-TMZ eras within the major known glioma prognostic molecular subtypes. Results: Among those who received TMZ, 5 SNPs were associated with overall survival, but not in those who did not receive TMZ. Only rs2308321-G, in Conclusions: Functional germline alterations within DNA repair genes were associated with TMZ sensitivity, measured by overall survival, among adults with glioma, these variants should be evaluated in prospective analyses and functional studies.

Indexed as

DNA damage repairgliomapharmacogenomicssurvivaltemozolomide

Identifiers

PMID39417102
PMCPMC11482862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.